A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of Anti-GD2 Antibody Drug Conjugate M3554 in Participants With Advanced Solid Tumors
Latest Information Update: 18 Mar 2025
At a glance
- Drugs M 3554 (Primary)
- Indications Glioblastoma; Neuroblastoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono Research & Development Institute
- 19 Nov 2024 Status changed from not yet recruiting to recruiting.
- 18 Oct 2024 Status changed to not yet recruiting.
- 07 Jun 2024 New trial record